MedTrace Logo

Comparing the Prognosis of Patients With HCC and PVTT Treated With Surgery Versus Locoregional Therapy.

NCT06248528 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1076

Last updated 2025-07-16

No results posted yet for this study

Summary

Hepatocellular carcinoma is prone to invade the portal vein and form portal vein thrombosis, and patients in this period are directly included in the advanced stages, i.e. Barcelona clinical liver cancer stage C. For the treatment of PVTT, there are differences between Eastern and Western guidelines, with systemic drugs being the standard of care in Western countries, while surgical treatment is often actively practiced in the Asia-Pacific region. More research is needed to explore the differences between these two approaches.

Conditions

Interventions

PROCEDURE

Liver resection

Patients in the intervention group received liver resection and postoperative adjuvant therapy

PROCEDURE

Locoregional therapy

Patients in the control group received locoregional therapy and systemic therapy

Sponsors & Collaborators

  • Chen Xiaoping

    lead OTHER

Principal Investigators

  • WanGuang Zhang · Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-01
Primary Completion
2024-12-31
Completion
2027-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06248528 on ClinicalTrials.gov